On July 15, 2021, Vastpro and Medicilon signed a strategic cooperation agreement in the Medicilon Chuansha Park to reach a long-term strategic cooperation relationship.
Vastpro president Huang Ping, CEO Zhu Wenfeng, Commercial Director Fang Yuan, Medicilon founder & CEO Chen Chunlin, Chief Scientific Officer Peng Shuangqing, Vice President of Business Development Department Cai Jinna, and Senior Director of Business Development Department Wang Mingying attended the signing ceremony and witnessed the signing together.
At the signing ceremony, Dr. Chunlin Chen, Founder & CEO of Medicilon, first extended a warm welcome to the visit of Vastpro and his entourage, and expressed his enthusiasm and confidence in the upcoming strategic cooperation between the two parties. Dr. Chen mentioned that Medicilon has worked for 17 years and has always been committed to providing pre-clinical R&D services. As of the end of 2020, Medicilon has assisted 121 cases to enter clinical trials through the approval of CFDA/NMPA, US FDA, and Australian Medicines Agency TGA, and more than 940 domestic and foreign cooperative customers. Rich experience in R&D and application has made Medicilon the leading one-stop preclinical comprehensive CRO in China.
Huang Ping, Chairman of Vastpro, said in his speech: “I am very pleased to establish a strategic partnership with Medicilon. We look forward to using Medicilon’s one-stop preclinical R&D platform to empower Vastpro to accelerate the development of new drugs. It is hoped that the two parties will work together based on their respective technical capabilities and superior resources to achieve a win-win cooperation in the field of new drug research and development, and bring more effective treatment options to patients around the world.”
Professor Peng Shuangqing, Chief Scientific Officer of Medicilon, emphasized: “Medicine will fully mobilize internal and external resources to promote the smooth progress of the preclinical IND application for the Vastpro project. It is hoped that the two parties will take this strategic cooperation agreement as an opportunity to further integrate the advantages of new drug research and development. Resources, we look forward to Vastpro’s ability to create more valuable new drugs for the society in the future, and Medicilon will give full support.”
Subsequently, the two parties conducted in-depth exchanges and discussions on future cooperation matters, and formally signed a strategic cooperation agreement. This agreement marks the establishment of a long-term and profound cooperative relationship between the two companies. It also means that the two parties will work together to develop a blue ocean of innovative drugs and provide patients with newer, earlier and more innovative therapies.
R&D has no end, and innovation has no end. Medicilon will continue to promote the construction of the R&D platform, accelerate the improvement of technological innovation services, and empower more pharmaceutical R&D innovators with more advanced technology and better services.
Shanghai VastPro is established on the basis of the core members of the synthetic chemistry team of the Shanghai Green Chemical Engineering Technology Research Center. The continuous green synthetic chemical technology and product process innovation and development capabilities are the company The company has extensive technology, equipment and management resources to support its core competitiveness. The development goal of VastProTech is to “synthesize useful molecules and be a leader in green synthesis technology and products”. The company is committed to the innovation and development of green synthetic chemistry technology, focusing on the green manufacturing of high-end pharmaceutical products, and is currently focusing on Carry out the development of innovative synthetic technology and product manufacturing for complex drug molecules based on natural products, realize closed loops of industry and commerce, create a professional industrial platform and business platform, and build a first-class green synthesis and green manufacturing enterprise for pharmaceuticals and material products.
Medicilon (stock code: 688202) was established in 2004 and is headquartered in Shanghai. It is committed to providing a full range of pre-clinical new drug research services for global pharmaceutical companies, research institutions and scientific researchers. Medicilon’s one-stop comprehensive service helps customers accelerate the development of new drugs with strong project management and more efficient and cost-effective R&D services. The services cover the entire process of pre-clinical new drug research in medicine, including drug discovery, pharmaceutical research and clinical trials. Pre-research. Medicilon has grown up with high-quality customers at home and abroad and provided new drug research and development services to more than 940 customers around the world. Medicilon will continue to base itself on a global perspective, focus on innovation in China, and contribute to human health!
Phone: +86 (21) 5859-1500